Please login to the form below

Not currently logged in
Email:
Password:

X4 appoints John Celebi as COO

He joins from Igenica Biotherapeutics

X4 Pharmaceuticals John CelebiCambridge, Massachusetts-based X4 Pharmaceuticals has appointed John Celebi as its new chief operating officer.

Celebi brings over 20 years of biotech industry experience to the role, and will take on responsibility for X4's business development, operations and corporate development.

Most recently, he served as chief business officer of Igenica Biotherapeutics, and has previously held senior positions at Agilent Technologies, ArQule, Biogen and Cyclis Pharmaceuticals.

Paula Regan, president and chief executive of X4, said: “John has a tremendous knowledge-base for evolving an emerging biotech company across the range of critical business capabilities.

“His experience will be essential to achieving X4's mission of developing novel CXCR4 therapies that have the potential to make a significant impact in the cancer treatment landscape, and we look forward to tapping into his business-building expertise as we continue to pursue the development of X4P-001 and our portfolio of CXCR4 inhibitors.”

22nd June 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics